Novo Nordisk (NOVO B) Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
NOVO B Community Fair Values
Create NarrativeSee what 1225 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 295.50 |
| 52 Week High | DKK 675.20 |
| 52 Week Low | DKK 266.90 |
| Beta | 0.40 |
| 1 Month Change | -19.35% |
| 3 Month Change | 1.48% |
| 1 Year Change | -53.01% |
| 3 Year Change | -38.97% |
| 5 Year Change | 28.48% |
| Change since IPO | 10,864.75% |
Recent News & Updates
Recent updates
Novo Nordisk A/S' (CPH:NOVO B) 26% Share Price Surge Not Quite Adding Up
Jan 17
Novo Nordisk's (CPH:NOVO B) Profits May Not Reveal Underlying Issues
Aug 13Analysts Have Been Trimming Their Novo Nordisk A/S (CPH:NOVO B) Price Target After Its Latest Report
Aug 08Novo Nordisk A/S' (CPH:NOVO B) Share Price Is Still Matching Investor Opinion Despite 26% Slump
Jul 31Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Jul 24Is Now The Time To Put Novo Nordisk (CPH:NOVO B) On Your Watchlist?
Jun 23Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 09Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price
Apr 24
EU#2 - From Humble Beginnings to Global Powerhouse
CagriSema – a combination therapy for obesity and diabetes that may be even more effective than Wegovy.We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease
Apr 07Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year
Mar 14Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year
Feb 28Novo Nordisk will dominate with GLP-1 products boosting an 8% revenue spike
Are there any products or services that could move sales or earnings meaningfully?Most Immediate Catalyst (1–2 Years):Established GLP-1 Products:Ozempic & Rybelsus: driving robust sales and market peNovo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's
Feb 10Shareholder Returns
| NOVO B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | -20.0% | -23.2% | -8.6% |
| 1Y | -53.0% | -54.1% | -26.8% |
Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned -54.1% over the past year.
Return vs Market: NOVO B underperformed the Danish Market which returned -26.8% over the past year.
Price Volatility
| NOVO B volatility | |
|---|---|
| NOVO B Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DK Market | 10.5% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: NOVO B's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: NOVO B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 69,150 | Maziar Doustdar | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOVO B fundamental statistics | |
|---|---|
| Market cap | DKK 1.25t |
| Earnings (TTM) | DKK 102.43b |
| Revenue (TTM) | DKK 309.06b |
Is NOVO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVO B income statement (TTM) | |
|---|---|
| Revenue | DKK 309.06b |
| Cost of Revenue | DKK 54.38b |
| Gross Profit | DKK 254.69b |
| Other Expenses | DKK 152.25b |
| Earnings | DKK 102.43b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 23.05 |
| Gross Margin | 82.41% |
| Net Profit Margin | 33.14% |
| Debt/Equity Ratio | 63.1% |
How did NOVO B perform over the long term?
See historical performance and comparisonDividends
Does NOVO B pay a reliable dividends?
See NOVO B dividend history and benchmarks| Novo Nordisk dividend dates | |
|---|---|
| Ex Dividend Date | Mar 27 2026 |
| Dividend Pay Date | Mar 31 2026 |
| Days until Ex dividend | 48 days |
| Days until Dividend pay date | 52 days |
Does NOVO B pay a reliable dividends?
See NOVO B dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 17:53 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 52 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Gerhard Schwarz | Baader Helvea Equity Research |
| James Gordon | Barclays |